GSK And Fleming Initiative Launch £45M AI-Powered Program To Tackle AMR

The Grand Challenges, set to launch in early 2026, will target major threats such as Gram-negative bacteria, Aspergillus, and Staphylococcus aureus.

Professor Lord Ara Darzi, Executive Chair of the Fleming Initiative, said: “In the 12 months since we announced our landmark partnership between GSK and the Fleming Initiative, a huge amount of progress has been made. Through our convening power, we have the world-leading expertise, facilities, capacity and vision in place to be able to launch these ambitious Grand Challenges.”

Tony Wood, Chief Scientific Officer, GSK, explained: “I’m delighted to combine GSKs leadership in antimicrobial science with world-leading research at Imperial College London. Together, with scaled datasets, emerging drug modalities and AI-driven models, we will open up new approaches for the discovery of novel antibiotics as well as anticipate and outpace the development of resistance to transform the treatment and prevention of serious infections.”

Read Also - Emm Raises $9M Seed To Launch Smart Menstrual Cup For Women’s Health

The programs will support approximately 50 UK-based scientific and academic roles, led by experts from Imperial College and GSK. Research areas include antibiotic discovery, fungal drug development, immune response modeling, predictive AI surveillance, clinical trials, and policy engagement.

Professor Hugh Brady, President of Imperial College London, said: “Antimicrobial resistance is a global challenge that no single lab or institution can solve alone. Tackling the rise of drug-resistant infections can only be done by bringing together a wide range of expertise – from across science, industry and policy, alongside public engagement.”

Professor Tim Orchard, chief executive of Imperial College Healthcare NHS Trust, added: “We urgently need new solutions and interventions for tackling drug-resistant infections, which will only be achieved if we pool our expertise.”

About GSK

GSK brings together science, technology, and expert talent to proactively tackle disease. By combining innovative research, advanced technologies, and collaborative expertise, the company accelerates the discovery, development and delivery of treatments and vaccines aiming to improve health outcomes worldwide and stay ahead of evolving medical challenges.